ATAD1 and malaria: In agreement with previous studies showing that Block 2 epitopes are the target of antibodies associated with protection from clinical malaria [3], [7], [24], [25], in this study antibodies to the MSP-1 hybrid showed a clear association with reduced malaria incidence in a cohort of Ghanaian children.